1
|
Mohamed SOO, Mohamedelmugadam RAA, Almardi SAM, Ahmed THM, Ibrahim MEH, Mohamedali AOO. Seroprevalence and Associated Outcomes of Parvovirus B19 Infection in Human Immunodeficiency Virus Patients: A Systematic Review. Avicenna J Med 2024; 14:185-193. [PMID: 40084227 PMCID: PMC11896723 DOI: 10.1055/s-0045-1801865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2025] Open
Abstract
Several case reports have highlighted the presence of serious clinical outcomes in patients with human immunodeficiency virus (HIV) related to parvovirus B19 (PVB19). However, epidemiological studies have produced inconsistent and varying results regarding the prevalence of PVB19 and its associated clinical outcomes in this population. These inconsistencies highlight the need for a thorough summary and analysis of present data to better understand burden and impact of PVB19 on HIV patients. This review aims to provide an overview of current evidence and identify areas for further research. Following the Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines, a comprehensive search was conducted across Medline/PubMed, Google Scholar, and World Health Organization Virtual Health Library Regional Portal. The pooled prevalence with the corresponding 95% confidence interval (CI) was measured using Comprehensive Meta-Analysis Software version 3.3. Publication bias was estimated based on Begg's test, Egger's test, and examination of the funnel plots. A total of 16 studies, with 2,122 HIV patients, were included in the meta-analysis. The pooled prevalence of detecting anti-PVB19 immunoglobulin G, anti-PVB19 immunoglobulin M, and PVB19 DNA particles among HIV patients was 43.6% (95% CI: 23.5-66.1%), 5.10% (95% CI: 2.10-12.10%), and 6.40% (95% CI: 4.10-9.90%), respectively. In the overall population of HIV patients, most of the included studies did not establish a statistically significant association between PVB19 infection and the occurrence of anemia. PVB19 infection is commonly detected in individuals with HIV. However, anemia due to PVB19 is not common in this population. Findings from a few studies suggest that PVB19 infection may contribute to anemia in individuals with advanced HIV disease or significant immunosuppression. Additional research is needed to confirm and clarify these relationships in individuals with HIV, particularly those with compromised immune systems.
Collapse
Affiliation(s)
- Sagad O. O. Mohamed
- Department of Pediatrics and Child Health, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | | | - Safa A. M. Almardi
- Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | - Tassnem H. M. Ahmed
- Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | - Malaz E. H. Ibrahim
- Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | | |
Collapse
|
2
|
Khamitova IV, Lavrentieva IN, Semenov AV. Algorithm for laboratory diagnostics of parvoviral infection in risk groups. Klin Lab Diagn 2022; 67:115-122. [PMID: 35192759 DOI: 10.51620/0869-2084-2022-67-2-115-122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Parvovirus infection (PVI) is widespread, characterized by airborne, bloodborne and vertical transmission routes. Parvovirus B19 (PVB19) exhibits tropism to erythropoietic cells. According to the increased likelihood principle of PVB19 infection and the severity of the consequences, immunocompromised individuals, especially those with hematological manifestations of diseases, are in increased risk group. Based on the own research results and analysis of the published data, we have proposed specific algorithms for PVI laboratory testing in individual risk groups, taking into account the peculiarities of the development and infection manifestation in each group: in HIV-infected patients, in oncohematological patients with to whom allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been prescribed (blood and bone marrow recipients), as well as in patients with chronic anemia of parasitic etiology. For each group, the main clinical or laboratory marker, treatment procedure, or patient physiological parameters have been determined, based on which it was recommended to test for PVI. For HIV-infected patients, the main criterion for PVI testing is persistent anemia. For oncohematological patients, the basis for PVI testing is allo-HSCT procedure, which is planned or performed for this particular patient. For malaria patients, the patient's age was considered as major criterion, since in malaria and PVI coinfected young children can lead to a fatal outcome. The proposed PVI diagnostics algorithms usein risk groups can help to predict the severe course of underlying disease associated with PVB19 infection, and timely correct the therapy used.
Collapse
Affiliation(s)
| | | | - A V Semenov
- Ekaterinburg Research Institute of Viral Infections
| |
Collapse
|
3
|
Nouri M, Kamakifar P, Khodabandehlou N, Sadri Nahand J, Tavakoli A, Norooznezhad F, Sorayyayi S, Babaei F, Mostafaei S, Moghoofei M. Association between Parvovirus B19 and anemia in HIV-infected patients. Med J Islam Repub Iran 2019; 33:137. [PMID: 32280643 PMCID: PMC7137816 DOI: 10.34171/mjiri.33.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Indexed: 11/05/2022] Open
Abstract
Background: Human parvovirus B19 (B19V) can cause anemia in some patients, including those with compromised immunity system. There are a few studies on molecular epidemiology of B19V and its association with anemia in Iran. Therefore, the aim of this study was to determine the B19V DNA, IgM, IgG, genotyping, and viral load in HIV patients in different groups of pregnant women, general population, injection drug users (IDU), and Elite controllers. Also, the possible association of B19V with anemia was studied.
Methods: In this case-control study, B19V DNA, anti-B19V IgM, anti-B19V IgG, viral load, and hemoglobin level were assessed in 113 HIV positive patients and 72 healthy controls. Also, CD4+ T cell counts and HIV load were measured in the patients’ group. All statistical analyses were done using STATA 14.2 software (Stata Corporation, College Station, Texas, USA). P value < 0.05 was considered statistically significant.
Results: Among HIV patients, 19 (16.8%) cases had B19V DNA, 3 (2.7%) had B19V IgM, and 7 (6.2%) had B19V IgG. In control group, the prevalence of B19V DNA, IgM, and IgG was 6 (8.33%), 7(9.7%), and 19 (26.4%), respectively. In subpopulations based on transmission routes, general population had the highest B19V IgG and DNA positivity prevalence and viral load level. There was no significant association between B19V antibodies and DNA with anemia.
Conclusion: The results demonstrated that B19V infection cannot be considered as a high-risk factor for anemia in adult HIV patients. However, further studies are needed to determine the exact role of B19V infection in HIV patients.
Collapse
Affiliation(s)
- Majid Nouri
- Golestan Hospital Research Center, Tehran, Iran
| | - Parvin Kamakifar
- Department of Microbiology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
| | - Niloofar Khodabandehlou
- Department of Internal Medicine, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Javid Sadri Nahand
- Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Ahmad Tavakoli
- Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Norooznezhad
- Infectious Diseases Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Saba Sorayyayi
- Department of Clinical Biochemistry, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Farhad Babaei
- Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Shayan Mostafaei
- Medical Biology Research Center, Institute of Health and Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.,Epidemiology and Biostatistics Unit, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohsen Moghoofei
- Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.,Medical Biology Research Center, Institute of Health and Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|
4
|
Sabahi M, Salehipour A, Kazemi A, Sadeghi M, Decaro N, Mozhgani SH, Jalilian FA, Yaghoobi MH. Prevalence and disease association of human parvovirus B19 in Iran: a systematic review. Future Virol 2019. [DOI: 10.2217/fvl-2019-0046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Aim: The prevalence of human parvovirus B19 (B19V) and its association with other diseases in Iran are yet to be systematically assessed. This study aimed to evaluate the prevalence and disease association of B19V across Iran from 2000 to 2019. Methods: The literature search, based on different keywords in different databases, was performed. A total of 29 eligible studies were included and the essential information was collected from each article. Results: The results of this study show a relatively high prevalence of the B19V-associated diseases in all age groups of the Iranian population. Conclusion: The transmission of B19V and its complications should be prevented by developing preventative strategies.
Collapse
Affiliation(s)
- Mohammadmahdi Sabahi
- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Arash Salehipour
- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Azin Kazemi
- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Mohammadreza Sadeghi
- Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland
| | - Nicola Decaro
- Department of Animal Health & Well-Being, Faculty of Veterinary Medicine of Bari, University of Bari, Bari, Italy
| | - Sayed-Hamidreza Mozhgani
- Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
- Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
| | - Farid Azizi Jalilian
- Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Mojtaba Hedayat Yaghoobi
- Department of Infectious Disease, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| |
Collapse
|
5
|
Pedranti MS, Rodriguez-Lombardi G, Bracciaforte R, Romano N, Lujan P, Ricchi B, Mautino J, Adamo MP. Parvovirus B19 in HIV+ adult patients with different CD4+ lymphocyte counts. J Med Microbiol 2017; 66:1715-1721. [PMID: 29095139 DOI: 10.1099/jmm.0.000629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
PURPOSE Human parvovirus B19 (B19V) can cause anemia in immunocompromised patients. We aimed to investigate the presence of B19V in HIV+ adults with different CD4+ T cell counts, to recognise the frequency of B19V in these different conditions and its possible association with anemia. METHODOLOGY We studied B19V specific IgM, IgG and DNA in 98 HIV+ patients and in 52 healthy individuals. HIV load, CD4+ counts and haemoglobin level were also determined in the patients. RESULTS No individual in the control group had detectable IgM, 41/52 (78.8 %) had IgG and 5/52 (9.6 %) had B19V DNA. Among HIV+ patients, we found 5/98 (5.1 %) IgM+, 66/98 (67.3 %) IgG+ and 15/98 (15.3 %) had B19V DNA (no significant differences between the two groups compared). Considering the CD4+ cell range in HIV patients, 37 had <200 CD4+ cells ml-1, 31 had 200-500, and 30 had >500. Anti-B19V IgG prevalence in patients with >500 CD4+ cells ml-1 was significantly higher than in the rest (P=0.004) and compared to the control (P=0.046). B19V DNA concentration was always <103 IU ml-1, including 5 healthy individuals and 15 HIV+ patients. There was no significant association between B19V IgM or DNA and anemia nor between B19V DNA and HIV load. CONCLUSIONS The results indicate that B19V is not a high-risk factor for anemia in adult HIV+ patients under HAART treatment. Further studies will contribute to elucidate the mechanisms and significance of B19V DNA prevalence/persistence in adults, independently of the CD4+ cell status.
Collapse
Affiliation(s)
- Mauro Sebastian Pedranti
- Institutode Virología 'Dr J. M. Vanella', Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Fundaciónpara el Progreso de la Medicina, Córdoba, Argentina
| | | | - Romina Bracciaforte
- Institutode Virología 'Dr J. M. Vanella', Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | | | - Pablo Lujan
- Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina
| | - Brenda Ricchi
- Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina
| | - Jorge Mautino
- Fundaciónpara el Progreso de la Medicina, Córdoba, Argentina
| | - Maria Pilar Adamo
- Institutode Virología 'Dr J. M. Vanella', Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| |
Collapse
|